Crizotinib Pathway, Pharmacokinetics/Pharmacodynamics

Pathway network for the Crizotinib Pathway, Pharmacokinetics/Pharmacodynamics SuperPath

Sources:

PharmGKB

Pathways in the Crizotinib Pathway, Pharmacokinetics/Pharmacodynamics SuperPath

#	Name	Source	Genes
1	Crizotinib Pathway, Pharmacokinetics/Pharmacodynamics	PharmGKB	ABCB1 AKT1 AKT2 AKT3 ALK AOX1 ARAF BAD BRAF CYP3A4 CYP3A5 EML4 HRAS JAK3 JUN JUNB KRAS MAP2K1 MAP2K2 MAPK1 MAPK3 MET MTOR NPM1 NRAS PDGFRB PIK3C2A PIK3C2B PLCG1 PLCG2 RAF1 ROS1 RPS6KB1 SLCO1B1 SLCO1B3 STAT3 STAT5A STAT5B (see all 38) (see less)
2	Capmatinib Pathway, Pharmacokinetics/Pharmacodynamics	PharmGKB	AOX1 CYP3A4 MET
3	Ziprasidone Pathway, Pharmacokinetics	PharmGKB	AOX1 CYP3A4

Gene overlap in member pathways for Crizotinib Pathway, Pharmacokinetics/Pharmacodynamics SuperPath

Ordered by rank within the SuperPath, via the multiplicity of each gene in the constituent pathways

#	Symbol	Description	Category	# Related Pathways
1	AOX1	Aldehyde Oxidase 1	Protein Coding	3
2	CYP3A4	Cytochrome P450 Family 3 Subfamily A Member 4	Protein Coding	3
3	MET	MET Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	2
4	ROS1	ROS Proto-Oncogene 1, Receptor Tyrosine Kinase	Protein Coding	1
5	BAD	BCL2 Associated Agonist Of Cell Death	Protein Coding	1
6	RPS6KB1	Ribosomal Protein S6 Kinase B1	Protein Coding	1
7	RAF1	Raf-1 Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	1
8	STAT3	Signal Transducer And Activator Of Transcription 3	Protein Coding	1
9	STAT5A	Signal Transducer And Activator Of Transcription 5A	Protein Coding	1
10	STAT5B	Signal Transducer And Activator Of Transcription 5B	Protein Coding	1
11	BRAF	B-Raf Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	1
12	ARAF	A-Raf Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	1
13	JAK3	Janus Kinase 3	Protein Coding	1
14	JUN	Jun Proto-Oncogene, AP-1 Transcription Factor Subunit	Protein Coding	1
15	JUNB	JunB Proto-Oncogene, AP-1 Transcription Factor Subunit	Protein Coding	1
16	AKT3	AKT Serine/Threonine Kinase 3	Protein Coding	1
17	PDGFRB	Platelet Derived Growth Factor Receptor Beta	Protein Coding	1
18	NPM1	Nucleophosmin 1	Protein Coding	1
19	NRAS	NRAS Proto-Oncogene, GTPase	Protein Coding	1
20	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	1
21	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	1
22	AKT2	AKT Serine/Threonine Kinase 2	Protein Coding	1
23	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	1
24	MTOR	Mechanistic Target Of Rapamycin Kinase	Protein Coding	1
25	ALK	ALK Receptor Tyrosine Kinase	Protein Coding	1
26	EML4	EMAP Like 4	Protein Coding	1
27	SLCO1B3	Solute Carrier Organic Anion Transporter Family Member 1B3	Protein Coding	1
28	MAPK1	Mitogen-Activated Protein Kinase 1	Protein Coding	1
29	MAPK3	Mitogen-Activated Protein Kinase 3	Protein Coding	1
30	MAP2K1	Mitogen-Activated Protein Kinase Kinase 1	Protein Coding	1
31	MAP2K2	Mitogen-Activated Protein Kinase Kinase 2	Protein Coding	1
32	ABCB1	ATP Binding Cassette Subfamily B Member 1	Protein Coding	1
33	PIK3C2A	Phosphatidylinositol-4-Phosphate 3-Kinase Catalytic Subunit Type 2 Alpha	Protein Coding	1
34	PIK3C2B	Phosphatidylinositol-4-Phosphate 3-Kinase Catalytic Subunit Type 2 Beta	Protein Coding	1
35	PLCG1	Phospholipase C Gamma 1	Protein Coding	1
36	PLCG2	Phospholipase C Gamma 2	Protein Coding	1
37	CYP3A5	Cytochrome P450 Family 3 Subfamily A Member 5	Protein Coding	1
38	SLCO1B1	Solute Carrier Organic Anion Transporter Family Member 1B1	Protein Coding	1

Disorders associated with Crizotinib Pathway, Pharmacokinetics/Pharmacodynamics SuperPath

according to GeneCards Suite gene sharing

#	Disorder	Type	Genes	Score
1	Rasopathy	Enrichment	BRAF, HRAS, KRAS, MAP2K1, MAP2K2, NRAS, RAF1	16.00
2	Noonan syndrome and noonan-related syndrome	Enrichment	BRAF, HRAS, KRAS, MAP2K1, MAP2K2, NRAS, RAF1	11.04
3	Noonan syndrome 1	Enrichment	BRAF, HRAS, KRAS, MAP2K1, MAP2K2, NRAS, RAF1	10.51
4	Melanocytic nevus syndrome, congenital	Enrichment	ALK, BRAF, HRAS, NRAS, RAF1	10.35
5	Lung non-small cell carcinoma	Enrichment	BRAF, HRAS, KRAS, MAP2K1, NRAS	10.16
6	Cardiofaciocutaneous syndrome 1	Enrichment	BRAF, KRAS, MAP2K1, MAP2K2	10.13
7	Cardiofaciocutaneous syndrome	Enrichment	BRAF, KRAS, MAP2K1, MAP2K2	10.13
8	Differentiated thyroid carcinoma	Enrichment	ALK, BRAF, HRAS, KRAS, NRAS	7.83
9	Langerhans cell histiocytosis	Enrichment	BRAF, MAP2K1, NRAS	7.69
10	Schimmelpenning-feuerstein-mims syndrome	Enrichment	HRAS, KRAS, NRAS	7.09
11	Nevus, epidermal	Enrichment	HRAS, KRAS, NRAS	6.15
12	Thyroid cancer, nonmedullary, 2	Enrichment	BRAF, HRAS, NRAS	6.15
13	Noonan syndrome 3	Enrichment	HRAS, KRAS, RAF1	6.15
14	Pilomyxoid astrocytoma	Enrichment	BRAF, KRAS, RAF1	6.15
15	Follicular thyroid carcinoma	Enrichment	BRAF, HRAS, NRAS	6.15
16	Lung cancer	Enrichment	ALK, BRAF, KRAS, MET	5.75
17	Acute promyelocytic leukemia	Enrichment	NPM1, STAT3, STAT5B	5.24
18	Lung cancer susceptibility 3	Enrichment	BRAF, KRAS, ROS1	5.14
19	Ras-associated autoimmune leukoproliferative disorder	Enrichment	KRAS, NRAS	5.12
20	Hyperbilirubinemia, rotor type	Enrichment	SLCO1B1, SLCO1B3	4.64
21	Large congenital melanocytic nevus	Enrichment	HRAS, NRAS	4.64
22	Chronic myelogenous leukemia, bcr-abl1 positive	Enrichment	KRAS, NRAS	4.34
23	Noonan syndrome with multiple lentigines	Enrichment	BRAF, RAF1	4.34
24	Hemimegalencephaly	Enrichment	AKT3, MTOR	4.12
25	Colorectal cancer	Enrichment	AKT1, BRAF, MET, NRAS	4.01
26	Breast adenocarcinoma	Enrichment	AKT1, KRAS	3.94
27	Lung squamous cell carcinoma	Enrichment	ALK, KRAS	3.94
28	Vitamin d-dependent rickets, type 3	Enrichment	CYP3A4	3.83
29	Capillary malformation-arteriovenous malformation 1	Enrichment	KRAS, MAP2K1	3.80
30	Leukemia, chronic myeloid	Enrichment	KRAS, NRAS	3.80
31	Renal cell carcinoma, papillary, 1	Enrichment	MET, MTOR	3.80
32	Gallbladder cancer	Enrichment	BRAF, KRAS	3.80
33	Ovarian cancer	Enrichment	AKT1, ALK, KRAS, MET	3.75
34	Leukemia, acute myeloid	Enrichment	KRAS, NPM1, NRAS	3.73
35	Osteofibrous dysplasia	Enrichment	MET	3.66
36	Deafness, autosomal recessive 97	Enrichment	MET	3.66
37	Autism 9	Enrichment	MET	3.66
38	Arthrogryposis, distal, type 11	Enrichment	MET	3.66
39	Arteriovenous malformation	Enrichment	HRAS, MAP2K1	3.57
40	Myopathy, x-linked, with excessive autophagy	Enrichment	HRAS, MAP2K1	3.47
41	Childhood hepatocellular carcinoma	Enrichment	MET	3.35
42	Papillary renal cell carcinoma	Enrichment	MET	3.35
43	Juvenile myelomonocytic leukemia	Enrichment	KRAS, NRAS	3.30
44	Lip and oral cavity carcinoma	Enrichment	BRAF, HRAS	3.30
45	Renal cell carcinoma	Enrichment	MET	3.18
46	Renal cell carcinoma, nonpapillary	Enrichment	MET, MTOR	3.11
47	Rhabdomyosarcoma	Enrichment	ALK, HRAS	3.05
48	Dandy-walker syndrome	Enrichment	BRAF, PDGFRB	2.99
49	Breast cancer	Enrichment	AKT1, JUN, KRAS	2.92
50	Arteriovenous malformations of the brain	Enrichment	BRAF, KRAS	2.90
51	Diffuse large b-cell lymphoma	Enrichment	BRAF, STAT3	2.90
52	Arthrogryposis, distal, type 1a	Enrichment	MET	2.75
53	Proteus syndrome	Enrichment	AKT1	2.55
54	Hypoinsulinemic hypoglycemia with hemihypertrophy	Enrichment	AKT2	2.55
55	Oculoectodermal syndrome	Enrichment	KRAS	2.55
56	Pallister-killian syndrome	Enrichment	ARAF	2.55
57	Premature aging syndrome, penttinen type	Enrichment	PDGFRB	2.55
58	Noonan syndrome 5	Enrichment	RAF1	2.55
59	Melorheostosis, isolated	Enrichment	MAP2K1	2.55
60	Noonan syndrome 7	Enrichment	BRAF	2.55
61	Leopard syndrome 3	Enrichment	BRAF	2.55
62	Neuroblastoma 3	Enrichment	ALK	2.55
63	Colchicine resistance	Enrichment	ABCB1	2.55
64	Cardiomyopathy, dilated, 1nn	Enrichment	RAF1	2.55
65	Cardiofaciocutaneous syndrome 3	Enrichment	MAP2K1	2.55
66	Myofibromatosis, infantile, 1	Enrichment	PDGFRB	2.55
67	Melanosis, neurocutaneous	Enrichment	NRAS	2.55
68	Noonan syndrome 6	Enrichment	NRAS	2.55
69	Noonan syndrome 13	Enrichment	MAPK1	2.55
70	Growth hormone insensitivity syndrome with immune dysregulation 2, autosomal dominant	Enrichment	STAT5B	2.55
71	Encephalopathy, acute transient	Enrichment	ABCB1	2.55
72	Immune dysregulation, autoimmunity, and autoinflammation	Enrichment	PLCG1	2.55
73	Oculoskeletodental syndrome	Enrichment	PIK3C2A	2.55
74	T-cell large granular lymphocyte leukemia	Enrichment	STAT3	2.55
75	Cardiofaciocutaneous syndrome 2	Enrichment	KRAS	2.55
76	Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 2	Enrichment	AKT3	2.55
77	Lymphangioma	Enrichment	BRAF	2.55
78	Inflammatory bowel disease 13	Enrichment	ABCB1	2.55
79	Phace association	Enrichment	BRAF	2.55
80	Melorheostosis	Enrichment	MAP2K1	2.55
81	Leopard syndrome 2	Enrichment	RAF1	2.55
82	Basal ganglia calcification, idiopathic, 4	Enrichment	PDGFRB	2.55
83	Cardiofaciocutaneous syndrome 4	Enrichment	MAP2K2	2.55
84	Autoinflammation, antibody deficiency, and immune dysregulation	Enrichment	PLCG2	2.55
85	Cowden syndrome 6	Enrichment	AKT1	2.55
86	Myeloid and lymphoid neoplasms associated with pdgfrb rearrangement	Enrichment	PDGFRB	2.55
87	Kosaki overgrowth syndrome	Enrichment	PDGFRB	2.55
88	Familial cold autoinflammatory syndrome 3	Enrichment	PLCG2	2.55
89	Autoimmune disease, multisystem, infantile-onset, 1	Enrichment	STAT3	2.55
90	Ocular pterygium-digital keloid dysplasia syndrome	Enrichment	PDGFRB	2.55
91	Trigonitis	Enrichment	RAF1	2.55
92	T-b+ severe combined immunodeficiency due to jak3 deficiency	Enrichment	JAK3	2.55
93	Capillary hemangioma	Enrichment	AKT3	2.55
94	Stat3-related early-onset multisystem autoimmune disease	Enrichment	STAT3	2.55
95	Acute myeloid leukemia with multilineage dysplasia	Enrichment	NPM1	2.55
96	Congenital pulmonary airway malformation	Enrichment	KRAS	2.55
97	Acute myeloid leukemia with npm1 somatic mutations	Enrichment	NPM1	2.55
98	Alk-positive anaplastic large cell lymphoma	Enrichment	ALK	2.55
99	Syringocystadenoma papilliferum	Enrichment	BRAF	2.55
100	Ganglioglioma	Enrichment	BRAF	2.55
101	Nongerminomatous germ cell tumor	Enrichment	BRAF	2.55
102	Phace syndrome	Enrichment	BRAF	2.55
103	Oculocerebrodental syndrome	Enrichment	PIK3C2A	2.55
104	Phakomatosis pigmentokeratotica	Enrichment	HRAS	2.55
105	Classic hairy cell leukemia	Enrichment	BRAF	2.55
106	Alk-positive large b-cell lymphoma	Enrichment	ALK	2.55
107	Chronic lymphoproliferative disorder of natural killer cells	Enrichment	STAT3	2.55
108	Neurocutaneous melanocytosis	Enrichment	NRAS	2.55
109	Akt2-related familial partial lipodystrophy	Enrichment	AKT2	2.55
110	Bladder cancer	Enrichment	HRAS, KRAS	2.53
111	Non-immune hydrops fetalis	Enrichment	HRAS, KRAS	2.47
112	Hepatocellular carcinoma	Enrichment	MET	2.31
113	Myeloproliferative disorder, chronic, with eosinophilia	Enrichment	PDGFRB	2.25
114	Costello syndrome	Enrichment	HRAS	2.25
115	Growth hormone insensitivity syndrome with immune dysregulation 1, autosomal recessive	Enrichment	STAT5B	2.25
116	Pulmonic stenosis	Enrichment	BRAF	2.25
117	Encephalocraniocutaneous lipomatosis	Enrichment	KRAS	2.25
118	Cebalid syndrome	Enrichment	MTOR	2.25
119	Infantile myofibromatosis	Enrichment	PDGFRB	2.25
120	Senior-loken syndrome 7	Enrichment	AKT3	2.25
121	Bardet-biedl syndrome 16	Enrichment	AKT3	2.25
122	Smith-kingsmore syndrome	Enrichment	MTOR	2.25
123	Acute myeloid leukemia without maturation	Enrichment	NPM1	2.25
124	Lymphomatoid papulosis	Enrichment	NPM1	2.25
125	Tafro syndrome	Enrichment	MAP2K2	2.25
126	Laron syndrome with immunodeficiency	Enrichment	STAT5B	2.25
127	Primary cutaneous anaplastic large cell lymphoma	Enrichment	NPM1	2.25
128	Wooly hair nevus	Enrichment	HRAS	2.25
129	Hereditary breast carcinoma	Enrichment	AKT1, KRAS	2.17
130	Severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-negative, nk cell-negative, due to adenosine deaminase deficiency	Enrichment	JAK3	2.08
131	Hyper-ige syndrome 1, autosomal dominant, with recurrent infections	Enrichment	STAT3	2.08
132	Ataxia-telangiectasia	Enrichment	BRAF	2.08
133	Tethered spinal cord syndrome	Enrichment	BRAF	2.08
134	Breast implant-associated anaplastic large cell lymphoma	Enrichment	STAT3	2.08
135	Hyper ige syndrome	Enrichment	STAT3	2.08
136	Spermatocytoma	Enrichment	HRAS	2.08
137	Myeloma, multiple	Enrichment	BRAF, KRAS	1.97
138	Diffuse gastric and lobular breast cancer syndrome	Enrichment	KRAS	1.95
139	Thyroid cancer, nonmedullary, 1	Enrichment	BRAF	1.95
140	Neurofibromatosis-noonan syndrome	Enrichment	MAP2K2	1.95
141	Megalencephaly-capillary malformation-polymicrogyria syndrome	Enrichment	AKT3	1.95
142	Chromosome 22q11.2 deletion syndrome, distal	Enrichment	MAPK1	1.95
143	Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 1	Enrichment	AKT3	1.95
144	Focal cortical dysplasia, type ii	Enrichment	MTOR	1.95
145	Cholangiocarcinoma	Enrichment	ROS1	1.95
146	Lung sarcomatoid carcinoma	Enrichment	KRAS	1.95
147	Craniopharyngioma	Enrichment	BRAF	1.95
148	Pilocytic astrocytoma	Enrichment	KRAS	1.95
149	Newborn respiratory distress syndrome	Enrichment	BRAF	1.95
150	Epidermolytic nevus	Enrichment	HRAS	1.95
151	Adenosine deaminase deficiency	Enrichment	JAK3	1.95
152	Isolated focal cortical dysplasia type ii	Enrichment	MTOR	1.95
153	Severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-positive, nk cell-negative	Enrichment	JAK3	1.86
154	Acute myeloid leukemia with maturation	Enrichment	NPM1	1.86
155	Primary hypereosinophilic syndrome	Enrichment	PDGFRB	1.86
156	Wilms tumor 5	Enrichment	BRAF	1.78
157	Inflammatory myofibroblastic tumor	Enrichment	ALK	1.78
158	Megacolon	Enrichment	AKT3	1.71
159	Overgrowth syndrome	Enrichment	MTOR	1.71
160	Rare autosomal recessive non-syndromic sensorineural deafness type dfnb	Enrichment	MET	1.71
161	Dilated cardiomyopathy	Enrichment	BRAF, RAF1	1.68
162	Basal ganglia calcification, idiopathic, 1	Enrichment	PDGFRB	1.65
163	Lymphoma, non-hodgkin, familial	Enrichment	BRAF	1.65
164	Neuroblastoma	Enrichment	ALK	1.65
165	Permanent neonatal diabetes mellitus	Enrichment	STAT3	1.65
166	Cardiomyopathy, familial hypertrophic, 4	Enrichment	BRAF	1.60
167	Primary hyperaldosteronism	Enrichment	BRAF	1.60
168	Ventricular septal defect	Enrichment	BRAF	1.60
169	Cowden syndrome	Enrichment	AKT1	1.60
170	Polymicrogyria	Enrichment	AKT3	1.56
171	Melanoma	Enrichment	BRAF	1.56
172	Inherited cancer-predisposing syndrome	Enrichment	MET	1.54
173	Gilbert syndrome	Enrichment	SLCO1B1	1.52
174	Epilepsy, idiopathic generalized	Enrichment	ABCB1	1.52
175	Specific learning disability	Enrichment	MAPK1	1.52
176	Meningioma	Enrichment	AKT1	1.48
177	Protein-deficiency anemia	Enrichment	NRAS	1.45
178	Nk-cell enteropathy	Enrichment	JAK3	1.45
179	Wilms tumor 1	Enrichment	BRAF	1.38
180	Hydrocephalus	Enrichment	PDGFRB	1.38
181	Lynch syndrome	Enrichment	KRAS	1.38
182	Rare genetic intellectual disability	Enrichment	MTOR	1.38
183	Hypertension, essential	Enrichment	CYP3A5	1.33
184	Melanoma, cutaneous malignant 1	Enrichment	BRAF	1.33
185	Giant cell glioblastoma	Enrichment	ROS1	1.33
186	Heart, malformation of	Enrichment	MAPK1	1.31
187	Dyskeratosis congenita	Enrichment	NPM1	1.28
188	Cardiomyopathy, familial hypertrophic, 1	Enrichment	RAF1	1.19
189	Pancreatic cancer	Enrichment	KRAS	1.17
190	Hydrops fetalis, nonimmune	Enrichment	HRAS	1.15
191	Severe covid-19	Enrichment	JAK3	1.11
192	Familial hypertrophic cardiomyopathy	Enrichment	RAF1	1.05
193	Severe combined immunodeficiency	Enrichment	JAK3	1.05
194	Left ventricular noncompaction	Enrichment	RAF1	1.03
195	Cerebral palsy	Enrichment	PDGFRB	0.98
196	Type 2 diabetes mellitus	Enrichment	AKT2	0.95
197	Gastric cancer	Enrichment	KRAS	0.94
198	Familial isolated dilated cardiomyopathy	Enrichment	RAF1	0.86
199	Hereditary breast ovarian cancer syndrome	Enrichment	KRAS	0.84
200	Autism spectrum disorder	Enrichment	MAP2K1	0.58
201	Microcephaly	Enrichment	MAPK1	0.53

¹ WikiPathways

² PubChem

³ R&D Systems

⁴ Reactome

⁵ GeneGo (Thomson Reuters)

⁶ QIAGEN

⁷ PharmGKB

⁸ Cell Signaling Technology

⁹ Sino Biological

¹⁰ Tocris

¹¹ MalaCards

Crizotinib Pathway, Pharmacokinetics/Pharmacodynamics

Pathway Network for Crizotinib Pathway, Pharmacokinetics/Pharmacodynamics

Pathway network for the Crizotinib Pathway, Pharmacokinetics/Pharmacodynamics SuperPath

Member Pathways for Crizotinib Pathway, Pharmacokinetics/Pharmacodynamics

Pathways in the Crizotinib Pathway, Pharmacokinetics/Pharmacodynamics SuperPath

Gene overlap in member pathways for Crizotinib Pathway, Pharmacokinetics/Pharmacodynamics SuperPath

Associated Genes for Crizotinib Pathway, Pharmacokinetics/Pharmacodynamics

Associated Disorders for Crizotinib Pathway, Pharmacokinetics/Pharmacodynamics

Disorders associated with Crizotinib Pathway, Pharmacokinetics/Pharmacodynamics SuperPath

STRING Interaction Network for Crizotinib Pathway, Pharmacokinetics/Pharmacodynamics

Sources for Crizotinib Pathway, Pharmacokinetics/Pharmacodynamics